U.S. FDA approved Ervebo first U.S.-licensed vaccine for prevention of Ebola virus disease
On Jul. 28, 2023, the U.S. Food and Drug Administration (FDA) approved Merck’s Ervebo, a vaccine for the prevention of Ebola virus disease caused by Zaire ebolavirus in individuals 12 months through 17 years of age.
Ervebo was approved for use in individuals 18 years of age and older since December 2019.
Tags:
Source: U.S. Food and Drug Administration
Credit:
